June Featured Cancer Clinical Trials

Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients with Newly Diagnosed or Recurrent Glioblastoma
CLTR 1314 | 14-483
Disease(s): Brain, Glioblastoma
See full trial information

A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician’s Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with germline BRCA1/2 Mutations
ZNCA 1114 | 14-656
Disease(s): Breast cancer
See full trial information

Safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of open-label study with multiple and (for non-responders) escalating subcutaneous doses of BI 655064 once a week in patients with chronic primary immune thrombocytopenic purpura
BIP 1Z14 | 15-042
Disease: Chronic Immune Thrombocytopenic Purpura
See full trial information

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation
AGSP 1Z14 | 15-124
Disease: Hematologic Malignancy, Leukemia, Acute Myeloid (AML), Myelodysplastic Syndrome (MDS)
See full trial information

A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia (AML)
SEGE 1914 | 15-144
Disease(s): Leukemia, Acute Myeloid (AML)
See full trial information

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
KARY 1414 | 14-1340
Disease: Lymphoma
See full trial information

A Phase II, Open-label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand
NCI 1615 | 15-119
Disease(s): Melanoma
See full trial information

A Phase 3, Study of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis who were Treated with Ruxolitinib
GSI 3Z14 | 15-048
Disease(s): Myelofibrosis
See full trial information

A Phase I/II, Multicenter, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
BIP 1914 | 14-1163
Disease(s): Myelodysplastic Syndrome (MDS)
See full trial information

A Phase 2, double-blind, randomized safety and efficacy study of PF-04449913 versus placebo with defined best supportive therapy allowed in both arms in patients with Myelofibrosis previously treated with one or more Janus kinase inhibitors
PFIZ 1Z14 | 14-1326
Disease: Myelofibrosis
See full trial information

TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) with the T790M Resistance Mutation
CLVS 1514 | 14-775
Disease(s): Non-small cell lung cancer (NSCLC)
See full trial information